Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling
- PMID: 39202032
- PMCID: PMC11355397
- DOI: 10.3390/jpm14080841
Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling
Abstract
The IMPACT-FH study implemented strategies (packet, chatbot, direct contact) to promote family member cascade testing for familial hypercholesterolemia (FH). We evaluated the impact of genetic counseling (GC) on medical outcomes, strategy selection, and cascade testing. Probands (i.e., patients with FH) were recommended to complete GC and select sharing strategies. Comparisons were performed for both medical outcomes and strategy selection between probands with or without GC. GEE models for Poisson regression were used to examine the relationship between proband GC completion and first-degree relative (FDR) cascade testing. Overall, 46.3% (81/175) of probands completed GC. Probands with GC had a median LDL-C reduction of -13.0 mg/dL (-61.0, 4.0) versus -1.0 mg/dL (-16.0, 17.0) in probands without GC (p = 0.0054). Probands with and without GC selected sharing strategies for 65.3% and 40.3% of FDRs, respectively (p < 0.0001). Similarly, 27.1% of FDRs of probands with GC completed cascade testing, while 12.0% of FDRs of probands without GC completed testing (p = 0.0043). Direct contact was selected for 47 relatives in total and completed for 39, leading to the detection of 18 relatives with FH. Proband GC was associated with improved medical outcomes and increased FDR cascade testing. Direct contact effectively identified FH cases for the subset who participated.
Keywords: cascade testing; familial hypercholesterolemia; genetic counseling; population genomic screening.
Conflict of interest statement
Kelly M. Morgan, Nicole L. Walters, Gemme Campbell-Salome, Megan N. Betts, Eric P. Tricou, Andrew Brangan, Zoe Lindsey-Mills, Alicia Johns, H. Lester Kirchner, and Alanna Kulchak Rahm declare no conflicts of interest. Mary P. McGowan: Advisory board for Novartis. Amy C. Sturm: Employee and Shareholder of 23andMe, Advisor to Nest Genomics. Laney K. Jones: Consultant for Novartis. The sponsor had no role in the design, execution, interpretation, or writing of the study.
Figures
Similar articles
-
IMPACT-FH Study for Implementing Innovative Family Communication and Cascade Testing Strategies for Familial Hypercholesterolemia.JACC Adv. 2024 Aug 14;3(9):101198. doi: 10.1016/j.jacadv.2024.101198. eCollection 2024 Sep. JACC Adv. 2024. PMID: 39238848 Free PMC article.
-
Reporting Modifications from the IMPACT-FH Study Using the FRAME-IS.Public Health Genomics. 2025;28(1):205-216. doi: 10.1159/000545974. Epub 2025 Apr 21. Public Health Genomics. 2025. PMID: 40258342
-
Utilizing innovative implementation strategies for familial hypercholesterolemia: Implementation outcomes from the IMPACT-FH study.J Clin Lipidol. 2024 Sep-Oct;18(5):e832-e843. doi: 10.1016/j.jacl.2024.07.011. Epub 2024 Jul 31. J Clin Lipidol. 2024. PMID: 39278768
-
Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.Ont Health Technol Assess Ser. 2022 Aug 23;22(3):1-155. eCollection 2022. Ont Health Technol Assess Ser. 2022. PMID: 36158868 Free PMC article.
-
Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.Atherosclerosis. 2021 Dec;338:7-14. doi: 10.1016/j.atherosclerosis.2021.09.014. Epub 2021 Oct 2. Atherosclerosis. 2021. PMID: 34753031
References
-
- Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., et al. European Atherosclerosis Society Consensus Panel, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013;34:3478–3490a. - PMC - PubMed
-
- Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., De Ferranti S., Faiella-Tommasino J., Forman D.E., et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous